Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Defining and Striving for HBV Cure: What’s in the Pipeline

Source: Addressing Key Challenges in Viral Hepatitis Management
In this podcast, an expert discusses the various definitions/types of HBV cure and different investigational approaches under evaluation for their potential to achieve cure.
person default
Carla Coffin, MD
Released: June 30, 2022

In this episode, Carla S. Coffin, MD, MSc, shares her thoughts on the different investigational approaches under evaluation for their potential to achieve HBV cure, including entry inhibitors, capsid inhibitors, siRNAs, immune modulators, TLR agonists, therapeutic vaccines, and checkpoint inhibitors.

Information on this Educational Activity

Faculty

Carla Coffin, MD

Professor of Medicine
Division of Gastroenterology and Hepatology
Department of Medicine
University of Calgary
Medical Director of Calgary Liver Unit
Division of Gastroenterology and Hepatology
Department of Medicine
Foothills Medical Centre
Calgary, Alberta, Canada

Carla S. Coffin, MD, MSc: consultant/advisor/speaker: Altimmune; research support: Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
AbbVie
Gilead Sciences, Inc.

Related Content

Dr Stefan Zeuzem discusses his take on new viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Stefan Zeuzem, MD Released: December 5, 2022

Dr Nancy Reau discusses her take on new viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Nancy Reau, MD Released: December 2, 2022

Expert selections of important viral hepatitis data from AASLD 2022, including studies of patients with HBV, HDV, and HCV, from Clinical Care Options (CCO)

Nancy Reau, MD Stefan Zeuzem, MD Released: November 16, 2022

Expert summaries of key data in older patients with HBV, from Clinical Care Options (CCO)

Graham R. Foster, FRCP, PhD Nancy Reau, MD Released: November 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings